In this retrospective single institutional study, we found stage III melanoma patients treated with LND and adjuvant RT whose tumor exhibited a BRAF mutation had significantly worse local–regional control compared to patients with BRAF negative (wild-type) tumors. The gene discussed is BRAF; the disease is neoplasm.